Scarica l'app Stockscreener
8.145
2.41%
-0.165
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.31
Aprire:
$8.32
Volume 24 ore:
23,338
Relative Volume:
0.07
Capitalizzazione di mercato:
$459.66M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
-3.3657
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
+5.46%
1M Prestazione:
+9.15%
6M Prestazione:
+100.74%
1 anno Prestazione:
-30.21%
Intervallo 1D:
$8.08
$8.40
Intervallo di 1 settimana:
$7.3566
$8.69
Portata 52W:
$3.555
$12.52
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta ATXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
8.145 | 468.97M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.70 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.07 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.97 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.26 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN
Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
Comparing Astria Therapeutics Inc. in custom built stock radars2025 Retail Activity & Verified Entry Point Signals - newser.com
How to forecast Astria Therapeutics Inc. trends using time seriesWeekly Gains Report & Consistent Profit Alerts - newser.com
Visual analytics tools that track Astria Therapeutics Inc. performanceJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Tick level data insight on Astria Therapeutics Inc. volatility2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20 - Investing.com Canada
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
Analyzing Astria Therapeutics Inc. with multi timeframe chartsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
How to interpret RSI for Astria Therapeutics Inc. stock2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Astria Therapeutics begins phase 3 long-term trial for HAE treatment - Investing.com Nigeria
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with - PharmiWeb.com
Astria Therapeutics (ATXS) Begins Phase 3 Trial for Hereditary A - GuruFocus
Astria Therapeutics initiates the phase 3 ORBIT-EXPANSE long-term trial of navenibart in people with hereditary angioedema - MarketScreener
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire
Astria Therapeutics, Inc. $ATXS Stock Position Lifted by Farther Finance Advisors LLC - Defense World
How strong is Astria Therapeutics Inc. stock balance sheetJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Predicting Astria Therapeutics Inc. trend using moving averages2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
What’s the recovery path for long term holders of Astria Therapeutics Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Using Ichimoku Cloud for Astria Therapeutics Inc. technicalsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
Will Astria Therapeutics Inc. outperform the marketRate Cut & Free Fast Gain Swing Trade Alerts - newser.com
Will breakout in Astria Therapeutics Inc. lead to full recovery2025 Analyst Calls & Capital Protection Trading Alerts - newser.com
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA - Business Wire
Will Astria Therapeutics Inc. bounce back from current supportPortfolio Return Report & Free Technical Confirmation Trade Alerts - newser.com
Momentum divergence signals in Astria Therapeutics Inc. chartStop Loss & Growth Focused Investment Plans - newser.com
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial - BioSpace
Astria Therapeutics expands phase 3 HAE trial to European Union By Investing.com - Investing.com Nigeria
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Astria Therapeutics (ATXS) Advances Phase 3 Trial for Hereditary Angioedema Treatment - GuruFocus
Astria Therapeutics expands phase 3 HAE trial to European Union - Investing.com India
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.07%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):